Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0501 • ACR Convergence 2020
Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study
David Simon¹, Koray Tascilar¹, Arnd Kleyer¹, Sara Bayat², Eleni Kampylafka², Axel Hueber³, Juergen Rech¹, Louis Schuster¹, Klaus Engel⁴, Michael Sticherling² and Georg Schett⁵, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ⁴Siemens Healthcare GmbH Digital Technology & Camp; Innovation, SHS DS DTI, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: We have previously reported that the presence of musculoskeletal pain in psoriasis patients is associated with a higher risk of developing psoriatic arthritis (PsA)…
Abstract Number: 0882 • ACR Convergence 2020
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
Frank Behrens¹, Philipp Sewerin², Eugenio De Miguel³, Yusuf Patel⁴, Anastas Batalov⁵, Eva Dokoupilova⁶, Christine Kleinmond⁷, Effie Pournara⁸, Ankita Shekhawat⁹, Claudia Jentzsch¹⁰, Annette Wiedon¹¹ and Xenofon Baraliakos¹², ¹CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull East Yorkshire, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ¹⁰Novartis Pharma GmbH, Nuremberg, Germany, ¹¹Novartis Pharma GmbH, Nurnberg, Germany, ¹²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…
Abstract Number: 0910 • ACR Convergence 2020
Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2
Philip Mease¹, Laura Coates², Filip Van den Bosch³, Philip Helliwell⁴, Dafna Gladman⁵, Leen Gilles⁶, Lien Gheyle⁶, Mona Trivedi⁷, Muhsen Alani⁸ and Robin Besuyen⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²University of Oxford, Oxford, United Kingdom, ³Ghent University Hospital, Ghent, Belgium, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences, Inc., Foster City, CA, ⁸Gilead Sciences, Inc. and University of Washington, Foster City, CA, ⁹Galapagos BV, Leiden, Netherlands
Background/Purpose: EQUATOR (NCT03101670) was a 16-week, Phase 2, double-blind, randomized placebo-controlled trial of filgotinib for PsA. At Week 16, placebo-treated patients could switch to filgotinib…
Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Olga Compán¹, Maria Elisa Acosta², Sonia Pastor², Guadalupe Manzano Canabal², Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Noelia Cubino², Ricardo Usategui⁵, Rogelio Gonzalez Sarmiento⁵, Olga Martinez Gonzalez⁶, Ana Isabel Turrión², Javier Del Pino-Montes² and Carlos Montilla Morales², ¹Hospital Universitario de Salamanca, ´Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, ⁶Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…
Abstract Number: 1369 • ACR Convergence 2020
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
Saima Chohan¹, Arthur Kavanaugh², Vibeke Strand³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Philip Mease⁶, ¹Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ²UC San Diego Health System, San Diego, CA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Tildrakizumab (TIL), an anti–interleukin-23p19 monoclonal antibody, is approved in the US, EU, and Australia for treatment of moderate to severe plaque psoriasis. A randomized,…
Abstract Number: 1780 • ACR Convergence 2020
Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review
Agna Neto¹, Rita Pinheiro Torres², Helena Donato³, Ana Filipa Mourão², Jaime Branco² and Fernando Pimentel-Santos⁴, ¹1. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, ²2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, ³4. Serviço de Documentação, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁴3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal
Background/Purpose: The onset of psoriatic arthritis (PsA) often occurs between the ages of 30 and 50 years. Accordingly, many female patients are diagnosed during childbearing…
Abstract Number: 123 • 2020 Pediatric Rheumatology Symposium
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ⁸, Pamela Weiss ⁹ and Timothy Beukelman ⁷ for the CARRA investigators, ¹University of Alberta, Edmonton, Canada, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Duke Children's Hospital & Health Center, Durham, North Carolina, ⁵Amgen, Long Beach, ⁶Florida, Gainesville, ⁷University of Alabama at Birmingham, Birmingham, ⁸Amgen, Inc, San Francisco, ⁹Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 290 • 2019 ACR/ARP Annual Meeting
In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease and its assessment is sometimes difficult. Perception of disease activity by patient and physician is frequently discordant…
Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Fatima Abji¹, Anastasiya Muntyanu ², Remy Pollock ¹, Rohan Machhar ¹, Justine (Yang) Ye ³, Vinod Chandran ⁴ and Dafna Gladman ⁵, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Toronto, University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
Abstract Number: 1204 • 2019 ACR/ARP Annual Meeting
Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial
M. Elaine Husni¹, Diane Harrison ², Elizabeth Hsia ³, Eric K H Chan ², Chenglong Han ², Shelly Kafka ⁴, Kim Hung Lo ², Lilianne Kim ² and Arthur Kavanaugh ⁵, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: In the randomized, phase 3, GO-VIBRANT study, more patients with psoriatic arthritis (PsA) achieved ACR 20/50/70 after 24 weeks IV treatment with the anti-TNFa…
Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Martin Bergman¹, Yusuf Yazici ², Laura Coates ³, Josef Smolen ⁴, M. Elaine Husni ⁵, Sven Richter ⁶, Lichen Teng ⁶ and Arthur Kavanaugh ⁷, ¹Drexel University College of Medicine, Stockholm, Sweden, ²New York University School of Medicine, New York, ³University of Oxford, Oxford, United Kingdom, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁶Celgene Corporation, Summit, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…
Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Dongze WU¹, Priscilla Wong ¹, Steven H.M. Lam ¹, Isaac T. Cheng ¹, Edmund K. Li ¹, Ling Qin ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA). Nonetheless, whether these…
Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Michaela Koehm¹, Sarah Ohrndorf ², Tanja Rossmanith ³, Hans-Eckhard Langer ⁴, Marina Backhaus ⁵, Gerd Burmester ⁶, Siegfried Wassenberg ⁷, Benjamin Köhler ⁸, Harald Burkhardt ¹ and Frank Behrens ¹, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Fraunhofer IME-TMP, Frankfurt, Germany, ⁴RHIO, Düsseldorf, Germany, ⁵Park-Klinik Weissensee, Berlin, Germany, ⁶Charité—University Medicine Berlin, Berlin, Germany, ⁷Centre of Rheumatology, Ratingen, Germany, ⁸Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].